Eliquis

Most-clicked pharma news for week ending April 1 2023: Signify Health acquisition, Ferring Research Institute shutdown, Jardiance sales increase, and more
Most-clicked pharma news for week ending April 1 2023: Signify Health acquisition, Ferring Research Institute shutdown, Jardiance sales increase, and more
CP Wire
CVS Health
Signify Health
M&A
Ferring Pharmaceuticals
Pfizer
Bristol Myers Squibb
Eli Lilly
Novo Nordisk
Boehringer Ingelheim
Jardiance
Ozempic
drug pricing
Eliquis
CMS
Flag link:
Most-clicked pharma news for week ending April 1 2023: Signify Health acquisition, Ferring Research Institute shutdown, Jardiance sales increase, and more
CVS Health
Signify Health
M&A
Ferring Pharmaceuticals
Pfizer
Bristol Myers Squibb
Eli Lilly
Novo Nordisk
Boehringer Ingelheim
Jardiance
Ozempic
drug pricing
Eliquis
CMS
Flag link:
Pfizer, BMS' Eliquis tops list of drugs destined for Medicare price negotiations in 2026
Pfizer, BMS' Eliquis tops list of drugs destined for Medicare price negotiations in 2026
Fierce Pharma
Pfizer
Bristol Myers Squibb
Eliquis
drug pricing
Inflation Reduction Act
CMS
Flag link:
ESC 2022 preview – who’s got the XI factor?
ESC 2022 preview – who’s got the XI factor?
EP Vantage
ESC 2022
Bristol Myers Squibb
JNJ
Bayer
Eliquis
Xarelto
bloodthinners
Lixiana
Pradaxa
Flag link:
CVS re-adds BMS, Pfizer's Eliquis to formulary after tough negotiations, patient pushback
CVS re-adds BMS, Pfizer's Eliquis to formulary after tough negotiations, patient pushback
Fierce Pharma
CVS Health
Bristol Myers Squibb
Pfizer
Eliquis
formularies
bloodthinners
Flag link:
Did J&J and BMS conspire on blood thinner price hikes? Congressional leaders want DOJ, FTC to look into it: report
Did J&J and BMS conspire on blood thinner price hikes? Congressional leaders want DOJ, FTC to look into it: report
Fierce Pharma
JNJ
Xarelto
Bristol Myers Squibb
Eliquis
drug pricing
blood thinners
FTC
Flag link:
The patent winter is coming
The patent winter is coming
EP Vantage
patents
biosimilars
patent cliff
Keytruda
Opdivo
Eliquis
Darzalex
Revlimid
Humira
Stelara
AbbVie
Merck
Bristol Myers Squibb
JNJ
Flag link:
Running behind Bristol Myers and J&J, Bayer inches forward in the next-gen blood thinner race
Running behind Bristol Myers and J&J, Bayer inches forward in the next-gen blood thinner race
Endpoints
Bayer
bloodthinners
asundexian
clinical trials
Eliquis
Bristol Myers Squibb
JNJ
Flag link:
JPM 2022: Bristol Myers plots 3 blockbuster launches to counter Revlimid's patent cliff
JPM 2022: Bristol Myers plots 3 blockbuster launches to counter Revlimid's patent cliff
Fierce Pharma
JPMHC 2022
Bristol Myers Squibb
Revlimid
patent cliffs
Opdivo
Eliquis
Reblozyl
Breyanzi
Flag link:
Bristol Myers Squibb, Amgen and Pfizer approach steepest patent cliffs among large drugmakers
Bristol Myers Squibb, Amgen and Pfizer approach steepest patent cliffs among large drugmakers
Fierce Pharma
patents
patent cliffs
Bristol Myers Squibb
Amgen
Pfizer
Revlimid
Eliquis
Enbrel
Otezla
Ibrance
Flag link:
Bristol Myers, Pfizer score another win in their Eliquis patent defense, protecting the blockbuster until 2028
Bristol Myers, Pfizer score another win in their Eliquis patent defense, protecting the blockbuster until 2028
Fierce Pharma
Bristol Myers Squibb
Pfizer
Eliquis
patents
FTC
Flag link:
J&J, Bayer's Xarelto scores FDA nod in post-surgery artery disease as partners try to catch up with Eliquis
J&J, Bayer's Xarelto scores FDA nod in post-surgery artery disease as partners try to catch up with Eliquis
Fierce Pharma
Pfizer
Bristol Myers Squibb
Bayer
JNJ
Xarelto
FDA
Eliquis
Flag link:
The top 15 blockbuster patent expirations coming this decade
The top 15 blockbuster patent expirations coming this decade
Fierce Pharma
patents
patent cliff
AbbVie
Humira
Merck
Keytruda
Bristol Myers Squibb
Revlimid
Pfizer
Eliquis
Regeneron
Eylea
JNJ
Stelara
Opdivo
GSK
Dolutegravir
Ibrance
Januvia
Eli Lilly
Trulicity
Novo Nordisk
Victoza
Amgen
Prolia
Xgeva
Novartis
Cosentyx
Takeda
Entyvio
Flag link:
Eliquis partners BMS and Pfizer join the pharma crowd urging doctor visits during COVID-19
Eliquis partners BMS and Pfizer join the pharma crowd urging doctor visits during COVID-19
Fierce Pharma
Pfizer
Bristol-Myers Squibb
Eliquis
DTC advertising
pandemic
COVID-19
Flag link:
ESC: Pfizer, BMS' Eliquis tops Xarelto, vitamin K drugs for site-specific bleeding risks in French real-world study
ESC: Pfizer, BMS' Eliquis tops Xarelto, vitamin K drugs for site-specific bleeding risks in French real-world study
Fierce Pharma
Pfizer
Bristol-Myers Squibb
Eliquis
Xarelto
site-specific bleeding
RWE
ESC
Flag link:
Bristol Myers, Pfizer fend off a key challenge to their top-selling heart drug
Bristol Myers, Pfizer fend off a key challenge to their top-selling heart drug
BioPharma Dive
Bristol-Myers Squibb
Pfizer
patents
Eliquis
generics
Delaware
Flag link:
As Bristol-Myers, Pfizer battle copycat challengers in court, FDA approves generics for blockbuster Eliquis
As Bristol-Myers, Pfizer battle copycat challengers in court, FDA approves generics for blockbuster Eliquis
Endpoints
Pfizer
Bristol-Myers Squibb
FDA
generics
bloodthinners
Eliquis
Micro Labs
Mylan
Flag link:
Pfizer, BMS look to early atrial fibrillation screening for potential Eliquis boost
Pfizer, BMS look to early atrial fibrillation screening for potential Eliquis boost
Fierce Pharma
Pfizer
Eliquis
Bristol-Myers Squibb
atrial fibrillation
Flag link:
Merck, BMS, AbbVie blockbusters will rule pharma sales in 2025: report
Merck, BMS, AbbVie blockbusters will rule pharma sales in 2025: report
Fierce Pharma
Merck
Keytruda
Bristol-Myers Squibb
Pfizer
Eliquis
AbbVie
Humira
Flag link:
ESC: New Pfizer, BMS real-world data could boost Eliquis in Europe
ESC: New Pfizer, BMS real-world data could boost Eliquis in Europe
Fierce Pharma
Pfizer
Bristol-Myers Squibb
Eliquis
Warfarin
bloodthinners
Europe
ESC
European Society of Cardiology
Flag link:

Pages